JP2025504682A5 - - Google Patents

Info

Publication number
JP2025504682A5
JP2025504682A5 JP2024545123A JP2024545123A JP2025504682A5 JP 2025504682 A5 JP2025504682 A5 JP 2025504682A5 JP 2024545123 A JP2024545123 A JP 2024545123A JP 2024545123 A JP2024545123 A JP 2024545123A JP 2025504682 A5 JP2025504682 A5 JP 2025504682A5
Authority
JP
Japan
Prior art keywords
lipid
mol
lipid nanoparticles
group
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050796 external-priority patent/WO2023144792A1/en
Publication of JP2025504682A publication Critical patent/JP2025504682A/ja
Publication of JP2025504682A5 publication Critical patent/JP2025504682A5/ja
Pending legal-status Critical Current

Links

JP2024545123A 2022-01-31 2023-01-30 ポリ(アルキルオキサゾリン)-脂質コンジュゲートおよびそれを含む脂質粒子 Pending JP2025504682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305211P 2022-01-31 2022-01-31
US63/305,211 2022-01-31
PCT/IB2023/050796 WO2023144792A1 (en) 2022-01-31 2023-01-30 Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same

Publications (2)

Publication Number Publication Date
JP2025504682A JP2025504682A (ja) 2025-02-14
JP2025504682A5 true JP2025504682A5 (https=) 2026-02-09

Family

ID=85199305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545123A Pending JP2025504682A (ja) 2022-01-31 2023-01-30 ポリ(アルキルオキサゾリン)-脂質コンジュゲートおよびそれを含む脂質粒子

Country Status (7)

Country Link
US (1) US20250114476A1 (https=)
EP (1) EP4472671A1 (https=)
JP (1) JP2025504682A (https=)
CN (1) CN118900701A (https=)
AU (1) AU2023211981A1 (https=)
CA (1) CA3248399A1 (https=)
WO (1) WO2023144792A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (https=) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
AU637800B2 (en) 1989-08-31 1993-06-10 City Of Hope Chimeric dna-rna catalytic sequences
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
WO1996011266A2 (en) 1994-10-05 1996-04-18 Amgen Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US20050119470A1 (en) 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US20050282188A1 (en) 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
WO2004090108A2 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US8883211B2 (en) 2008-07-10 2014-11-11 Serina Therapeutics, Inc. Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
US20110313017A1 (en) 2010-01-13 2011-12-22 Protiva Biotherapeutics, Inc. Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates
US12233132B2 (en) * 2021-02-09 2025-02-25 Serina Therapeutics, Inc. Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

Similar Documents

Publication Publication Date Title
JP2025504682A5 (https=)
KR102198736B1 (ko) 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도
EP1664316B1 (en) Polyethyleneglycol-modified lipid compounds and uses thereof
JP2022544652A5 (https=)
JP2022501064A5 (https=)
JP2023534206A5 (https=)
CN116744979A (zh) 包含甘露糖的脂质纳米颗粒或其应用
JP2023518944A5 (https=)
KR102465349B1 (ko) 신규 이온화 지질 및 이를 포함하는 지질 나노입자
WO2019102606A1 (ja) 疾患部位特異的リポソーム製剤
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
CN118632690A (zh) 含有可生物降解的酯键的可电离脂质和包含其的脂质纳米颗粒
KR102156324B1 (ko) 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물
BR112020006191A2 (pt) copolímeros em blocos anfifílicos, micelas e métodos para tratamento ou prevenção de insuficiência cardíaca
CN116589435A (zh) 用于核酸递送的可电离脂质及其组合物
KR20240083166A (ko) 폐를 표적장기로 하는 생분해성 지질나노입자 약물 전달 제형 및 이의 활용
CN118766874A (zh) 一种吸入式制剂、迭代优化流程及其应用
Tu et al. Active drug targeting of disease by nanoparticles functionalized with ligand to folate receptor
CN115745788B (zh) 一种可电离脂质化合物及其制备方法和应用
WO2023245175A2 (en) Targeted nanomedicine for treating arterial disease
JP2020521004A (ja) c(RGD−ACP−K)修飾血中滞留型リポソーム
JP2025538206A (ja) 脂質-荷電分子コンジュゲート、吸入可能な脂質ナノ粒子、その製造方法、および使用
RU2024125225A (ru) Конъюгаты поли(алкилоксазолин)-липид и содержащие их липидные частицы
JP2023536119A5 (https=)
CN100379404C (zh) 用于减少脂质体诱导的补体激活的脂质体组合物